In for a shot |
Averaged down, as this is simply nuts. Panic and shorters |
It will bounce imho. Just a bit of patience needed. |
Three year low, also way below what they were 30 years ago, incredible. |
Fell more than larger vaccine makers and those involved with the covid vaccine. Absolutely laughable |
Price collapse is hard to believe! |
Panache. Wonder if you might see £11? The uncertainty is only going to grow for a while. |
Pharmaceutical companies were the main FTSE 100 losers. GSK was down 3.2%, Croda International lost 2.9%, and AstraZeneca was down 2.5%.
"The announcement of vaccine-sceptic Robert F Kennedy Junior as health secretary pick for the incoming Trump administration has spooked investors in the sector, with US drug companies also seeing their shares come under significant pressure overnight," explained Mould. "The impact on the sector is hard to judge fully at this stage but, at the very least, it will cause a good deal of uncertainty.". |
Please beware of PURCHASEATTHETOP(RICHARD BOBARTH)
RICHARD BOBARTH news article www.mirror.co.uk/news/uk-news/conman-jailed-swindling-41000-working-8810621.amp |
FYI to people on here - purchaseatthetop is this guy. Do not engage especially if he tries to DM you hTTps://www.mirror.co.uk/news/uk-news/conman-jailed-swindling-41000-working-8810621.amp |
Nothing like making your health supreme somebody who says part of his brain was eaten by a worm… |
Indeed it has. Got my 13 quid. |
I'll add a few more (way too many atm though) when the US opens |
dplewis1 - 09 Oct 2024 - 18:35:11 - 33395 of 33674 Glaxosmithkline - The recovery - GSK
Pander isn't getting his 13 quid that's for sure
Seems the market has decided otherwise! |
1033 GMT - The vaccine sector is under pressure after the nomination of Robert F. Kennedy Jr. as U.S.'s Health Secretary, but the market reaction looks overdone, Bryan Garnier Research analysts write. Kennedy is feared for his anti-vax positions, the analysts say. Shares in Pfizer, GSK, Moderna and BioNTech all dropped in Thursday's U.S. session and the sell-off has continued in Europe. Bavarian Nordic shares are down 16%, Valneva shares 6.1% lower with GSK and Sanofi both down 2.7%. However, the analysts believe the vaccine recommendation process has rigid structures in place, and U.S. governmental action will likely focus more on increased transparency and public information on vaccine risks and benefits. "We thus expect no impact on Valneva and Bavarian Nordic business near-term." |
My post yesterday was before that announcement, d'oh! However I'm not talking about daily movements, just look at the longer term chart. |
got a few more at 13.11 |
It's a buy at these levels imho. |
Which is why I am buying......I presume you will wait till it's back to £16, like all amateurs? |
Oh,dear this is plumbing |
Post-election jitters. GSK is expected to report earnings of 91p per share this year, and that then rises to 143p in 2025 and 159p in 2026. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
